Repetitive Transcranial Magnetic Stimulation as an Alternative Therapy for Cognitive Impairment in Alzheimer’s Disease: A Meta-Analysis
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recent studies have indicated that repetitive transcranial magnetic stimulation (rTMS) could improve cognitive function in people with Alzheimer's disease (AD). Yet the results are inconclusive. OBJECTIVE: This meta-analysis aimed to evaluate recent rTMS studies conducted in mild to moderate AD patients. METHODS: PubMed, Embase, MEDLINE databases and Science Direct were searched for studies of rTMS treatment on AD patients with cognitive impairment published before February 2015. The relevant primary outcomes of cognition were extracted from those included studies. A crude standardized mean difference (SMD) with 95% confidence interval (CI) was calculated by using random effect models. RESULTS: Seven studies with a total of 94 mild to moderate AD patients were included in this meta-analysis. A significant overall rTMS treatment effect on cognition was found for all AD patients (p = 0.0008, SMD = 1.00, 95% CI = 0.41-1.58). Stratification analysis showed that this effect is stimulation frequency- and hemisphere-dependent. High frequency stimulation (>1.0 Hz) (p < 0.05) but not low frequency stimulation (≤1.0 Hz) (p > 0.05) was significantly effective in improving the cognition of AD patients. Further, rTMS stimulation on right dorsolateral prefrontal cortex (DLPFC) and bilateral DLPFC (p < 0.05), but not on the left DLPFC (p > 0.05) was significantly effective in improving cognitive function of AD patients. A significant effect was observed in the rTMS subgroup (p < 0.05), rather than in the rTMS+drug subgroup (p > 0.05). CONCLUSION: This meta-analysis supports that high frequency rTMS stimulation on right- or bilateral-DLPFC has significant therapeutic effect on cognitive function in patients with mild to moderate AD. Due to small number of studies included, more well-controlled rTMS studies should be evaluated in AD patients in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Forecasting the global burden of Alzheimer's disease
Brookmeyer, R., Johnson, E., Ziegler‐Graham, K., & Arrighi, H. M. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.04.381 · Cited by 3,370
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932 · cited 1×
“mon in elderly people [1], accounting for 80% of”
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
A review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
Levkovitz, Y., Isserles, M., Padberg, F., Lisanby, S. H., Bystritsky, A., Xia, G., Tendler, A., Daskalakis, Z. J., Winston, J. L., Dannon, P., et al. (2015) · World Psychiatry · doi:10.1002/wps.20199 · Cited by 442
Guse, B., Falkai, P., & Wobrock, T. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-009-0333-7 · Cited by 340 · cited 1×
“Several recent reviews have highlighted that repetitive transcranial magnetic stimulation (rTMS) could improve cognitive functions including executive, learning, memory, and attention in people with AD, Parkinson’s disease, and mild cognitive impairment (MCI) [20–24].”
Differential diagnosis of Alzheimer's disease
Geldmacher, D. S., & Whitehouse, P. J. (1997) · Neurology · doi:10.1212/wnl.48.5_suppl_6.2s · Cited by 122 · cited 1×
“oping AD increases markedly after the age of 65, and that risk doubles every five years between the ages of 65 and 95 [7].”
Eliasova, I., Anderkova, L., Marecek, R., & Rektorova, I. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.08.036 · Cited by 115
Cited by
Chou, Y.-H., Ton That, V., & Sundman, M. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.020 · Cited by 319
The Association Between the Gut Microbiota and Parkinson’s Disease, a Meta-Analysis
Shen, T., Yue, Y., He, T., Huang, C., Qu, B., Lv, W., & Lai, H.-Y. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.636545 · Cited by 219
“com/) was applied to digitize and extract sufficient data (Fedorov, 2012; Liao et al., 2015; Tang et al., 2015).”
MethodKumar, S., Zomorrodi, R., Ghazala, Z., Goodman, M. S., Blumberger, D. M., Cheam, A., Fischer, C., Daskalakis, Z. J., Mulsant, B. H., Pollock, B. G., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3292 · Cited by 181
Wu, X., Ji, G.-J., Geng, Z., Wang, L., Yan, Y., Wu, Y., Xiao, G., Gao, L., Wei, Q., Zhou, S., et al. (2022) · Brain Stimulation · doi:10.1016/j.brs.2021.11.007 · Cited by 109
“For future clinical application, this iTBS protocol is recommended for patients with mild or moderate stages of AD [59], especially those with MMSE scores 21.”
Cheng, C. P. W., Wong, C. S. M., Lee, K. K., Chan, A. P. K., Yeung, J. W. F., & Chan, W. C. (2018) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4726 · Cited by 63
“Also, meta-analysis of Liao et al. (2015) did not include two large-scale RCTs (Drumond Marra et al., 2015; Wu et al., 2015), both of which suggested a significant therapeutic effect of high-frequency rTMS over the left DLPFC region.”
BackgroundMethodResultInfluential
Metadata
- Authors
- Liao, X., Li, G., Wang, A., Liu, T., Feng, S., Guo, Z., Tang, Q., Jin, Y., Xing, G., McClure, M. A., Chen, H., He, B., Liu, H., & Mu, Q.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2015-09-09
- Volume
- 48
- Issue
- 2
- Pages
- 463-472
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2280809537
- Cited by
- 99
- References
- 11
- FWCI
- 0.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.